US OptionsDetailed Quotes

YMAB241220C12500

Watchlist

0.05
-0.31-86.11%

15min DelayClose Dec 20 15:59 ET

0.05High0.05Low

Y-mAbs Therapeutics Stock Discussion

Jaguar8

Dec 8 18:55

NEWS SATURDAY

$Y-mAbs Therapeutics (YMAB.US)$
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...

Trytosaveabit

Dec 8 15:51

Watching Monday/week 12/9! Data released Saturday and more to come Monday 12/9/24

$Y-mAbs Therapeutics (YMAB.US)$ Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Moomoo AI

Mar 24 10:01

Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Moomoo AI

Mar 3 08:57

The company's cash runway and revenue growth are positive. Its cash burn relative to market capitalisation is low, indicating potential for more cash raising with minimal dilution or borrowing. The company's cash burn is not a concern, suggesting it is well-positioned for continued growth funding.